Gynecologic Cancer

The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Platinum-based chemotherapy, when administered before chemoradiotherapy, improved progression-free and overall survival for patients with locally advanced cervical cancer.

Information about gynecologic cancers found on TikTok may not be credible or reliable, according to findings from a recent study.

The overexpression of the gene, BRD4, may be the cause of chemotherapy resistance in patients with high-grade serous ovarian cancer, according to research.

The FDA granted a priority review for a new supplemental Biologics License Application to Keytruda plus concurrent chemoradiotherapy for patients with locally advanced cervical cancer.

Rachelle’s unexpected departure reminded me I need to express my appreciation to these special, beloved providers now.

I always enjoyed writing about my summers, but this is what I would write today.

I faced cancer thrice and chose life each time — not because of some flowery will to live, but because I’m stubborn and wanted to prove that cancer is not the boss of me.

Here’s a look back at the therapies for solid cancers that gained FDA approval this summer.

Jemperli plus chemotherapy has been approved for the treatment of adults with primary advanced or recurrent mismatch repair deficient (dMMR) or microsatellite instability-high endometrial cancer.

High-level results from a phase 3 trial demonstrated that treatment with batiraxcept did not improve progression-free survival in patients with platinum-resistant ovarian cancer.

The Food and Drug Administration approved Jemperli with chemotherapy and then alone for patients with dMMR or MSI-H advanced endometrial cancer.

Patients with HER2-expressing cancers using Enhertu saw significant improvements in progression-free survival and overall survival.

We recently asked our audience of patients, survivors and caregivers about the ongoing cisplatin and carboplatin shortage. Here’s what they had to say.

Adding Keytruda to chemoradiotherapy significantly improved progression-free survival for patients with newly diagnosed high-risk locally advanced cervical cancer.

While inflammation may not be associated with certain cancer-related symptoms, it can impact depression and physical activity levels in anyone, recent research showed.

The final overall survival results of the PAOLA-1/ENGOT-ov25 trial confirmed the drug combination as “one of the standards of care” for some populations of patients with ovarian cancer.

Patients with platinum-resistant or refractory ovarian cancer experienced deep responses and survival benefits in a trial assessing immunotherapy with chemotherapy.

Researchers are looking for other ways to disrupt tumor cells in a way that better engages the immune system by exposing it to tumor antigens.

While my taste buds have returned to normal after cancer treatment, my desire to cook and eat has not.

Treatments for advanced endometrial cancer have progressed and improved with the use of immunotherapy with chemotherapy.

A survey of cancer centers found that the majority of large centers are facing cisplatin and carboplatin shortages, and some are changing or delaying treatment because of it.

Jemperli plus carboplatin and paclitaxel also helped patients with early endometrial cancer maintain their health-related quality of life throughout follow-up.

Results of the Canadian Cancer Trials Group CX.5/SHAPE trial could lead to surgical de-escalation among patients with cervical cancer.

I lost my hair during cancer treatment, but now that it’s growing back, I no longer obviously look like a patient.

The benefit obtained from Keytruda plus chemotherapy in patients with persistent, recurrent or metastatic cervical cancer occurred regardless of whether they also received Avastin.

After going through cancer, Mother’s Day feels a bit different.

Patients with advanced or recurrent endometrial cancer derived a survival benefit from Jemperli plus chemotherapy.

Patients with advanced or recurrent endometrial cancer treated with Keytruda plus chemotherapy had improved progression-free survival compared with chemotherapy alone.

Researchers used an AI model to identify patients with endometrial cancer who had a low or high risk for cancer returning to another part of the body, also known as distant recurrence.